Özet:

Parkinson's disease is a chronic progressive neurodegenerative disorder characterized by tremor, bradikinesis, rijidity and postural balance disorders, which is formed due to loss of dopaminergic neurons in the nigrostrial pathway. Parkinson's disease affects 5 million people worldwide and is known as the second common neurodegenerative disorder. Current treatments are not intended to change the neurodegenerative process, but to improve the quality of life with symptomatic treatments. Although Levodopa Parkinson's disease is an effective drug in the treatment of motor symptoms, due to diskinesis and motor fluctuations after a period of time, it is necessary to either change the levadopa dosage or add other medications to the treatment (such as dopamine agonists, catecol-O-methyltransferase inhibitors, monoamin oxidase type B inhibitors). Therefore, new methods of treatment have been developed as an alternative to conventional treatments. These approaches are often symptomatic to improve dyskinesis and motor volatility, and are also included in the repair approaches that are still in the initial stages, such as neurotrophic factors and cell transplantation. Symptomatic treatment approaches include deep brain stimulation, subcutan apomorphine, carbidopa/levodopa intestinal gel, the Accordion Pill, prolonged release amantadine, adenosine receptor antagonists, metabot¬ropic glutamate receptor antagonists and gene treatment.®This article discussed the positive and negative aspects of the therapeutic approaches mentioned above.Some of these approaches have recently started to be used, while some are still in the clinical research stage.All of these approaches are a new source of hope for Parkinson’s patients.

Anahtar Kelimeler: